With Nature stating that almost 60% of clinical professionals expect eConsent adoption to continue post-pandemic, it is clear the benefits behind a digitally-enabled consent process have garnered trust. But a recent Medable poll found that the informed consent process still remains rooted in paper. This reliance on paper comes at a cost though: low enrollment, poor patient retention and issues around site compliance leading to inspection findings and costly trial delays.
Alex Burrington, CTI Principal of Vertex, and Andrew Mckinnon, VP, GM of eConsent t at Medable discuss:
- Common myths that continue to persist around eConsent
- How to improve comprehension with patient-centric consent
- How to use a digital consent management tool to improve trial compliance, quality and oversight